First Principles Advisory Group
First Principles Advisory Group is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at First Principles Advisory Group.
First Principles Advisory Group is a company.
Key people at First Principles Advisory Group.
Key people at First Principles Advisory Group.
First Principles Advisory Group is a boutique management consultancy specializing in biopharma strategy at the intersection of commerce, government, and science, particularly in pharmaceuticals and biotechnology.[1][2][3] It provides tailored strategic, commercial, operational, and market research solutions to over 50 clients, including Fortune 100 pharma companies, venture capitalists, portfolio companies, US and Canadian government agencies, and universities.[2] The firm's flexible team combines strategic depth, commercial expertise, scientific/clinical orientation, and financial experience to support clients from early-stage startups through commercialization and big pharma portfolio management.[1][2]
With an estimated annual revenue of $1-1.9M and 11-12 employees based in Burlingame, California, the firm focuses on key services like commercial strategy (e.g., portfolio decisions, go/no-go analysis), operations execution, market research across therapeutic areas, and disease area strategy.[1][2][3]
Founded in 2009, First Principles Advisory Group emerged as a specialized consultancy in the biopharma sector, headquartered in Burlingame, California (with addresses listed as 533 Airport Blvd or 235 Montgomery St).[1][3][4] Its backstory centers on addressing gaps at the "fulcrum of commercial, scientific, and clinical strategy," drawing from practical domain experience in an industry where such interdisciplinary expertise is rare.[1][2] Key team members include Richard Koo (VP), Stephen Jones (Engagement Manager), and others like Toby Kilroy (Consultant) and Lindsey Davis (Analyst), reflecting a small, agile structure that has maintained 11-12 employees despite a -40% growth dip last year.[1][3]
The firm's evolution emphasizes bridging startups to commercialization, as evidenced by client testimonials from CFOs and COOs at venture-funded bio-oncology and clinical-stage biopharma companies, highlighting its role in transitions from R&D to market.[2]
First Principles Advisory Group rides the biopharma innovation wave, where converging commercial pressures, regulatory complexities, and scientific breakthroughs demand specialized guidance—especially as biotech funding rebounds and therapies advance from platforms to markets.[2] Its timing aligns with a maturing ecosystem: post-2009 founding, it supports VC portfolio companies and governments amid rising therapeutic complexity (e.g., bio-oncology), while market forces like personalized medicine and supply chain strains favor its operations expertise.[1][2]
The firm influences the ecosystem by enabling efficient scaling—e.g., go/no-go decisions and commercialization plans that accelerate viable science to market, indirectly bolstering startup survival rates and big pharma portfolios in a sector where 90% of biotechs fail pre-launch.[2]
With biopharma's pipeline swelling amid AI-driven drug discovery and global manufacturing shifts, First Principles is positioned for steady growth by expanding its niche in operations and market research for emerging modalities like cell/gene therapies.[2] Trends like regulatory harmonization (US/Canada) and VC-biotech synergies will amplify demand for its interdisciplinary model, potentially reversing recent employee contraction through targeted hires in data analytics.[1][3]
Its influence may evolve toward deeper VC advisory and government partnerships, solidifying its role as a pivotal bridge in biopharma's next commercialization surge—echoing its core strength in turning first-principles science into market reality.[2]